Blog
New data show that Zigakibart maintains protein -pleasure remission and kidney function in IgA nephropathy
05
Jun
Jun
The new 100-week-old data from the ongoing study of the 1/2 phase of Zigakibart, the monoclonal anti-theaprile antibody examined, strengthen its potential as the treatment of IgA IgA (Igan) nephropathy. The arrangements presented today on 62ND The ERA Congress has permanent proteinage remission, a stable function of the kidneys and a calming safety profile. Igan […]